Fig. 2From: Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerEffects of selinexor in breast cancer models. a Seven breast cancer cell lines were treated with vehicle or 800 nM selinexor, a physiologically achievable dose. Cells were lysed and blotted with the indicated antibodies. b The bands were quantified and normalized to their respective β-actin controls. Values are shown as relative protein levels vs vehicle control of cell lines treated with selinexorBack to article page